COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE
On 14 May 2020 an annual general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39-41, 1560 Copenhagen V with the following agenda:
Agenda:
- Appointment of a chairman of the meeting
- Report of the chairman of the board of directors
- Presentation of the annual report together with a resolution for its adoption
- Resolution to appropriate the profit or cover the loss
- Election of members of the board of directors
- Appointment of an auditor
- Any other business
Re. 1 Appointment of a chairman
Ulrik Bayer, attorney-at-law, was appointed chairman of the meeting.
The chairman of the meeting noted that out of a total of 693,602.80 share capital 439,314 were represented and out of a total of 8,670,035 voting rights 5,491,425 were represented – either in person or by a power of attorney. On this basis the chairman found that the ordinary general meeting was quorum. The chairman further stated that the ordinary general meeting was duly summoned.
Re. 2 Report of the chairman of the board of directors
The chairman of the board of directors submitted its report on the company’s operations from 1 January 2019 to 31 December 2019. The shareholders noted the report without objections.
Re. 3 Presentation of the annual report together with a resolution for its adoption
The company’s annual report for the period from 1 January 2019 to 31 December 2019 was presented together with a resolution for its adoption.
The resolution was adopted unanimously and by all votes represented.
Re. 4 Resolution to appropriate the profit or cover the loss
The annual report showed that the profit for the year amounted to DKK 1,702,421. The board of directors proposed a resolution to transfer DKK 1,702,421 to retained earnings and to pay out DKK 0 as dividends.
The resolution was adopted unanimously and by all votes represented.
Re. 5 Election of members of the board of directors
A resolution was proposed to re-elect chairman Marianne Wier, Jeppe Bo Petersen and Søren Melsing Frederiksen as members of the board of directors. A resolution was proposed to elect Søren Kjær, co-founder and COO, as a new member of the board of directors instead of Rolf Steno.
The resolution was adopted unanimously and by all votes represented.
Re. 6 Appointment of an auditor
A resolution was proposed to re-appoint the company’s auditors. The resolution was adopted unanimously and by all votes represented.
Re. 7 Any other business
There was no further business to be transacted.
The shareholders resolved to grant Ulrik Bayer, attorney-at-law, power of attorney to file the resolutions passed by the general meeting with the Danish Business Authority and to make such amendments to the resolutions and the documents which may prove necessary in order to obtain registration with the Danish Business Authority.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO, Phone: +45 31770060, E-mail: presse@stenocare.com
Certified Adviser
STENOCARE’s Certified Adviser will be Keswick Global AG, Reg. FN 332389 h, Hoffingergasse 16/1/6, 1120 Vienna, Austria, telephone number +43 1 740 408045. E-mail: info@keswickglobal.com
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of producing and supplying medical cannabis to patients. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company was the first to offer medical cannabis oil products that complies with the strict Danish regulatory requirements. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.